Interim feasibility analysis of PROACT: of 64,092 genotyped biobank participants, 2,495 had high coronary polygenic risk despite low clinical risk; 21.5% of 1,314 invited opted in, and 102 of the first 204 imaged had subclinical plaque on CCTA.
RCTn = 204
Abou-Karam et al. Polygenic Risk Based Detection and Treatment of Subclinical Coronary Atherosclerosis in the PROACT Clinical Trials